C4 Therapeutics
C4 Therapeutics, based in Watertown, MA, specializes in developing targeted protein degradation therapies and collaborates with major pharmaceutical companies like Merck and Roche.
Company Overview
C4 Therapeutics is a biopharmaceutical company headquartered in Watertown, MA. The company specializes in developing targeted protein degradation (TPD) therapies aimed at treating various cancers. Their innovative drug discovery process leverages the proprietary TORPEDO® platform, enabling the design of novel therapeutic agents.
Strategic Collaborations
C4 Therapeutics has established multiple strategic partnerships to advance its research and development efforts. Notably, they have a discovery research collaboration with Merck KGaA, Darmstadt, Germany. Additionally, they have entered into a license and research collaboration with Merck to develop degrader-antibody conjugates (DACs). Other key partners include Roche, Biogen, Betta Pharmaceuticals, and Merck KGaA, Darmstadt, Germany.
TORPEDO® Platform
C4 Therapeutics utilizes the TORPEDO® platform to aid drug discovery. This proprietary technology enables the company to design and develop targeted protein degradation therapies efficiently. The platform supports the creation of innovative degraders that can address various challenging targets within the oncology space.
Pipeline and Clinical Trials
The pipeline of C4 Therapeutics includes several promising compounds aimed at treating cancer. Key pipeline assets include Cemsidomide, CFT1946, and CFT8919. CFT1946 is currently undergoing a Phase 1/2 clinical trial targeting BRAF V600 mutant solid tumors. CFT8919 is an allosteric BiDAC degrader that targets EGFR with L858R mutation in non-small cell lung cancer. These pipeline candidates reflect the potential of the company's targeted protein degradation approach.
Global Partnerships
C4 Therapeutics has established significant global partnerships to extend the reach of their therapies. In collaboration with Betta Pharmaceuticals, they are developing CFT8919 for the Chinese market, including Hong Kong, Macau, and Taiwan. Such alliances enable the company to leverage regional expertise and accelerate the development and commercialization of their novel therapies.